Loading viewer...
earnings
Format: PDF earnings
Karyopharm Therapeutics presented first quarter 2022 financial results and business updates on May 5, 2022, featuring commercial highlights for XPOVIO and pipeline updates for selinexor and eltanexor. The presentation covers financial guidance for 2022 net product revenue and R&D/SG&A expenses, along with clinical development progress across multiple myeloma and diffuse large B-cell lymphoma indications.
conference
34 Pages
earnings
17 Pages
Natera, Inc.
BNY Mellon Q3 2016 Financial Highlights
earningsearnings
25 Pages
Bank of New York Mellon
Fortive Q3 2023 Earnings Release – October 25
earningsearnings
28 Pages
Fortive Corporation